Tomorrow, we are expecting a big pharma sales rep at our anaesthetic department. He is pushing the α2-agonist Dexmedetomidine. It has been around for a decade but I have no experience with it myself and as far as I know it is only now being introduced in my little part of the world. It is being hyped as the first new intensive care sedative introduced in a decade.

Some of us have been using clonidine for a long time, but dexmedetomidine makes bolder claims. Anyway, before I get on the local bandwagon I’ll be reading this:
(Well, I intend to.)

Dexmedetomidine in children: current knowledge and future applications.
Mason KP, Lerman J.
Anesth Analg. 2011 Nov;113(5):1129-42. Epub 2011 Aug 4. Review.

Prolonged infusions of dexmedetomidine in critically ill patients.
Guinter JR, Kristeller JL.
Am J Health Syst Pharm. 2010 Aug;67(15):1246-53. Review.

Dexmedetomidine: an updated review.
Gerlach AT, Dasta JF.
Ann Pharmacother. 2007 Feb;41(2):245-52.


This entry was posted in Anesthesia, Intensive Care. Bookmark the permalink.


  1. Elizabeth says:

    It is very interesting that the alpha-2 agonists have multiple applications as a blood pressure reducer, anxiolytic, and ultimately an opioid-sparing medication, as you mentioned. I am excited to see more research on this drug class as time goes on. Thank you for sharing!

Leave a Reply

Your email address will not be published. Required fields are marked *